Our pathway analysis identified several well-known members of Nrf2 antioxidant signaling in cardiac hypertrophy, such as glutamate cysteine ligase subunits (GCLM and GCLC) and glutathione-disulfide reductase (GSR)45,46, but we also detected several Nrf2 targets not previously associated with myocyte hypertrophy, including flavin-containing monooxygenase 1 (FMO1), ferritin light chain (FTL) and aflatoxin B1-aldehyde reductase (AFAR/AKR7A2). The gene discussed is FMO1; the disease is cardiac hypertrophy.